Author: Amrutha mahankali
Jul2026
Ariana Pharma and USIL Therapeutics Announce AI-Powered Collaboration to Advance Development of UT-241 in Acute Radiation Syndrome
Ariana Explainable Artificial Intelligence applied to mechanistic modelling of radiation-induced oxidative stress, bridging pre-clinical evidence to clinical outcomes. Ariana Pharma® and USIL Therapeutics, a Luxembourg-based biopharmaceutical company developing innovative cytoprotective therapies, today announced a collaboration to develop a mechanistic AI model supporting the clinical evaluation of UT-241 in acute radiation syndrome (ARS). The collaboration addresses […]
Jul2026
A New Chapter: Ariana Pharma Appoints Thomas Turcat as Chief Executive Officer
Ariana Pharma announces the appointment of Thomas Turcat as Chief Executive Officer The transition marks a new chapter for Ariana Pharma as it expands the reach of its explainable AI technology with in-house drug development expertise to transform small, heterogeneous clinical cohorts into regulatory-ready results that are logical and rule-association-based while leveraging Thomas’ broad commercial […]
Nov2025
Ariana Pharmaceuticals Publishes New Study on AI-Driven Discovery of Genomic Biomarkers for Liver Toxicity Risk
Ariana Pharmaceuticals is proud to announce the publication of a new Real-World Evidence study: “eXp AI-driven Discovery of Genomic Biomarkers for Liver Toxicity Risk – A UK Biobank Case Study.” in The Pharmacogenomics Journal This research showcases how Ariana’s explainable Artificial Intelligence (eXp AI) and proprietary KEM® (Knowledge Extraction & Management) platform can identify genomic […]